Microsoft vs Zoetis Inc — how do they compare? Microsoft trades at $493.38 (market cap $3.74T), while Zoetis Inc trades at $72.33 (market cap $31.14B). The key difference: Microsoft is far larger — about 120.1× Zoetis Inc's market cap, and Zoetis Inc pays the higher dividend (2.81%). Which is the better fit depends on your goals.
| MSFT | ZTS | |
|---|---|---|
Market Cap | $3.74T | $31.14B |
Volume | 36,654,621 | — |
Sector | Technology | Health |
52-Week High | $542.07 | $156.76 |
52-Week Low | $352.83 | $71.91 |
Enterprise Value | $3.72T | $38.70B |
Dividend Yield | 0.72% | 2.81% |
Signals from Pluang's Aura AI — not financial advice
Microsoft (MSFT) trades at $492.85, down 2.61% over the past day, with a bullish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $4.74 exceeding the $4.24 estimate. Revenue growth remains robust, reaching $281.72 billion in 2025, while profitability metrics like a 40.31% net income margin and 34.04% ROE highlight operational strength. Recent news emphasizes Microsoft's leadership in AI and cloud computing, though concerns over capital expenditures persist.
The outlook for MSFT is positive, driven by AI integration and cloud demand, with a consensus price target of $555.00 implying ~13% upside. Risks include competitive pressures in AI, high valuation multiples, and macroeconomic volatility. Institutional sentiment is strongly bullish, with 80.49% of analysts rating it a buy, supporting a favorable long-term investment case despite near-term volatility.
Zoetis (ZTS) trades at $74.86, up 3.03% today but facing bearish technical signals with 16 sell indicators. The company reported mixed Q2 2026 results, beating EPS estimates but missing revenue expectations, while cutting full-year guidance due to softer pet healthcare demand. Strong fundamentals include a 27.69% net margin and 64.91% ROE, though valuation metrics show a P/E of 12.29 and P/S of 3.41.
The stock presents a value opportunity with analyst consensus target of $94.90 (27% upside), but faces near-term headwinds from competitive pressures and class action lawsuits. Investors should weigh strong profitability against slowing growth in companion animal segments and technical bearishness.
Trailing returns across standard periods
Latest headlines on both assets
Microsoft Corporation develops, manufactures, licenses, sells, and supports software products. The Company offers operating system software, server application software, business and consumer applications software, software development tools, and Internet and intranet software. Microsoft also develops video game consoles and digital music entertainment devices.
Read more on MSFT →Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →